Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 10/2012

01-10-2012 | Original article

Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer

Matched-pair analysis

Authors: Prof. Dr. M. Pinkawa, M.D. Piroth, R. Holy, N. Escobar-Corral, M. Caffaro, V. Djukic, J. Klotz, M.J. Eble

Published in: Strahlentherapie und Onkologie | Issue 10/2012

Login to get access

Abstract

Background

Hydrogel spacer is an innovative method to protect the rectal wall during prostate cancer radiotherapy. Clinical effects are not well known.

Methods

Patients have been surveyed before, at the last day, and 2–3 months after radiotherapy using a validated questionnaire (Expanded Prostate Cancer Index Composite). Median dose to the prostate in the spacer subgroup (SP) was 78 Gy in 2 Gy fractions. The results were independently compared with two matched-pair subgroups (treated conventionally without spacer): 3D conformal 70.2 Gy in 1.8 Gy fractions (3DCRT) and intensity-modulated radiotherapy (IMRT) 76 Gy in 2 Gy fractions. There were 28 patients in each of the three groups.

Results

Baseline mean bowel bother scores were 96 points in all subgroups. Similar mean changes (SP 16, 3DCRT 14, IMRT 17 points) were observed at the end of radiotherapy. The smallest difference resulted in the spacer subgroup 2–3 months after radiotherapy (SP 2, 3DCRT 8, IMRT 6 points). Bowel bother scores were only significantly different in comparison to baseline levels in the spacer subgroup. The percentage of patients reporting moderate/big bother with specific symptoms did not increase for any item (urgency, frequency, diarrhoea, incontinence, bloody stools, pain).

Conclusion

Moderate bowel quality-of-life changes can be expected during radiotherapy irrespective of spacer application or total dose. Advantages with a spacer can be expected a few weeks after treatment.
Literature
1.
Akimoto T, Muramatsu H, Takahashi M et al (2004) Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys 60:1033–1039PubMedCrossRef
2.
Al-Mamgani A, Putten WL van, Heemsbergen WD et al (2008) Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72:980–988PubMedCrossRef
3.
Bohrer M, Schröder P, Welzel G et al (2008) Reduced rectal toxicity with ultrasound-based image guided radiotherapy using BAT™  (b-mode acquisition and targeting) for prostate cancer. Strahlenther Onkol 184:674–678PubMedCrossRef
4.
Brenner DJ (2004) Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 60:1013–1015PubMedCrossRef
5.
Dearnaley D, Syndikus I, Sumo G et al (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trials. Lancet Oncol 13:43–54PubMedCrossRef
6.
Ferlay J, Parkin DM, Steliarova-Foucher E (2008) Estimates of cancer incidence and mortality in Europe 2008. Eur J Cancer 46:765–781CrossRef
7.
Fiorino C, Sanguineti G, Cozzarini C et al (2003) Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 57:953–962PubMedCrossRef
8.
Geier M, Astner ST, Duma MN et al (2012) Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy. Strahlenther Onkol (in press)
9.
Goldner G, Potter R, Battermann JJ et al (2012) Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients. Strahlenther Onkol 188:305–310PubMedCrossRef
10.
Goldner G, Sljivic S, Oismueller R et al (2011) Prostate cancer radiotherapy in Austria: overview on number of patients, intention to treat, and treatment techniques based on data from 2007. Strahlenther Onkol 187:279–283PubMedCrossRef
11.
Goldner G, Tomicek B, Becker G et al (2007) Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients. Int J Radiat Oncol Biol Phys 67:78–83PubMedCrossRef
12.
Hatiboglu G, Pinkawa M, Vallée J et al (2012) Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int (in press)
13.
Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71PubMedCrossRef
14.
ICRU (1993) ICRU report 50: prescribing, recording and reporting photon beam therapy. International Commission on Radiation Units and Measurements
15.
Kupelian PA, Potters L, Khuntia D et al (2004) Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy ≥ 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25–33PubMedCrossRef
16.
Michalski JM, Winter K, Purdy JA et al (2005) Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 62:706–713PubMedCrossRef
17.
Moman MR, Heide UA van der, Kotte AN et al (2010) Long-term experience with transrectal and transperineal implantations of fiducial gold markers in the prostate for position verification in external beam radiotherapy; feasibility, toxicity and quality of life. Radiother Oncol 96:38–42PubMedCrossRef
18.
Osoba D, Rodrigues G, Myles J et al (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMed
19.
Peinemann F, Grouven U, Bartel C et al (2011) Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol 60:881–893PubMedCrossRef
20.
Pinkawa M, Corral NE, Caffaro M et al (2011) Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol 100:436–441PubMedCrossRef
21.
Pinkawa M, Holy R, Piroth MD et al (2010) Consequential late effects after radiotherapy for prostate cancer—a prospective longitudinal quality of life study. Radiat Oncol 5:27PubMedCrossRef
22.
Pinkawa M, Holy R, Piroth MD et al (2011) Interpreting the clinical significance of quality of life score changes after radiotherapy for localized prostate cancer. Curr Urol 5:137–144CrossRef
23.
Pinkawa M, Piroth MD, Holy R et al (2011) Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 187:479–484PubMedCrossRef
24.
Pinkawa M, Asadpour B, Gagel B et al (2006) Prostate position variability and dose-volume histograms in radiotherapy for prostate cancer with full and empty bladder. Int J Radiat Oncol Biol Phys 64:856–861PubMedCrossRef
25.
Pinkawa M, Pursch-Lee M, Asadpour B et al (2008) Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction organ motion. Strahlenther Onkol 184:679–685PubMedCrossRef
26.
Potters L, Klein EA, Kattan MW et al (2004) Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71:29–33PubMedCrossRef
27.
Prada PJ, Fernandez J, Martinez AA et al (2007) Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 69:95–102PubMedCrossRef
28.
Prada PJ, Gonzalez H, Menendez C et al (2009) Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy 8:210–217PubMedCrossRef
29.
Schulze D, Liang J, Yan D et al (2009) Comparison of various online IGRT strategies: The benefits of online treatment plan re-optimization. Radiother Oncol 90:367–376PubMedCrossRef
30.
Viani GA, Stefano EJ, Alfonso SL (2009) Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 74:1405–1418PubMedCrossRef
31.
Volz-Sidiropoulou E, Pinkawa M, Fischedick K et al (2008) Factor analysis of the Expanded Prostate Cancer Index Composite (EPIC) in a patient group after primary (external beam radiotherapy and permanent iodine-125 brachytherapy) and postoperative radiotherapy for prostate cancer. Curr Urol 2:122–129CrossRef
32.
Wei JT, Dunn RL, Litwin MS et al (2000) Development and validation of the expanded prostate cancer index composite (epic) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56:899–905PubMedCrossRef
33.
Yaparpalvi R, Hong L, Mah D et al (2009) ICRU reference dose in an era of intensity-modulated radiation therapy clinical trials: correlation with planning target volume mean dose and suitability for intensity-modulated radiation therapy dose prescription. Radiother Oncol 89:347–352CrossRef
34.
Zucca S, Carau B, Solla I et al (2011) Prostate image-guided radiotherapy by megavolt cone-beam CT. Strahlenther Onkol 187:473–478PubMedCrossRef
Metadata
Title
Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer
Matched-pair analysis
Authors
Prof. Dr. M. Pinkawa
M.D. Piroth
R. Holy
N. Escobar-Corral
M. Caffaro
V. Djukic
J. Klotz
M.J. Eble
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Strahlentherapie und Onkologie / Issue 10/2012
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-012-0172-6

Other articles of this Issue 10/2012

Strahlentherapie und Onkologie 10/2012 Go to the issue

Review article

Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity

Originalien

Angst und Depressivität bei Tumorpatienten im Verlauf der radioonkologischen Behandlung

Original article

High symptom improvement and local tumor control using stereotactic radiotherapy when given early after diagnosis of meningioma

Original article

Impact of zoledronic acid on control of metastatic spinal cord compression

Mitteilungen der Fachgesellschaften

Mitteilungen

Literatur kommentiert

Sind nichtkrebsdingte Todesursachen durch Suizid, kardiovaskuläre Erkrankung oder Pneumonie bei Patienten mit einem Karzinom der Mundhöhle oder Oropharynx vermeidbar?